Collegium Pharma (NASDAQ: COLL) reported Q3 EPS of ($0.50), $0.16 worse than the analyst estimate of ($0.34). Revenue for the quarter came in at $70.2 million versus the consensus estimate of $74.79 million.

For earnings history and earnings-related data on Collegium Pharma (COLL) click here.